[go: up one dir, main page]

MX2017014463A - Cabazitaxel y su uso para tratar cancer. - Google Patents

Cabazitaxel y su uso para tratar cancer.

Info

Publication number
MX2017014463A
MX2017014463A MX2017014463A MX2017014463A MX2017014463A MX 2017014463 A MX2017014463 A MX 2017014463A MX 2017014463 A MX2017014463 A MX 2017014463A MX 2017014463 A MX2017014463 A MX 2017014463A MX 2017014463 A MX2017014463 A MX 2017014463A
Authority
MX
Mexico
Prior art keywords
cabazitaxel
treating cancer
cancer
solvate
hydrate
Prior art date
Application number
MX2017014463A
Other languages
English (en)
Inventor
Chadjaa Mustapha
François DEDIEU Jean-
Gupta Sunil
SELLAMI Dalila
SEMIOND Dorothée
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53177311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017014463(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MX2017014463A publication Critical patent/MX2017014463A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2205/00—General identification or selection means
    • A61J2205/30—Printed labels

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)

Abstract

La presente invención se refiere al compuesto que tiene la fórmula (I): (ver Fórmula) que puede estar en forma de base o en la forma de un hidrato o un solvato, para su uso como un medicamento en el tratamiento de cáncer en pacientes con insuficiencia hepática.
MX2017014463A 2015-05-13 2016-05-12 Cabazitaxel y su uso para tratar cancer. MX2017014463A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305720.3A EP3093014A1 (en) 2015-05-13 2015-05-13 Cabazitaxel and its use for treating cancer
PCT/EP2016/060759 WO2016180943A1 (en) 2015-05-13 2016-05-12 Cabazitaxel and its use for treating cancer

Publications (1)

Publication Number Publication Date
MX2017014463A true MX2017014463A (es) 2018-03-21

Family

ID=53177311

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014463A MX2017014463A (es) 2015-05-13 2016-05-12 Cabazitaxel y su uso para tratar cancer.

Country Status (15)

Country Link
US (1) US20160331717A1 (es)
EP (3) EP3093014A1 (es)
JP (1) JP2018516890A (es)
KR (1) KR20180006417A (es)
CN (1) CN108135878A (es)
AU (1) AU2016259775A1 (es)
CA (1) CA2985408A1 (es)
EA (1) EA201792502A1 (es)
ES (1) ES2774101T3 (es)
IL (1) IL255541A (es)
MX (1) MX2017014463A (es)
PL (1) PL3294285T3 (es)
PT (1) PT3294285T (es)
TW (1) TW201705950A (es)
WO (1) WO2016180943A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102770131A (zh) 2009-10-29 2012-11-07 安万特医药股份有限公司 卡巴他赛的新颖抗肿瘤用途
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
US5847170A (en) 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
ES2248684T3 (es) 2003-07-02 2006-03-16 Scheuten Glasgroep Procedimiento para la fabricacion de un acristalamiento contra incendios.
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
CN102770131A (zh) * 2009-10-29 2012-11-07 安万特医药股份有限公司 卡巴他赛的新颖抗肿瘤用途
CN102781237A (zh) * 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
US20140221389A1 (en) * 2011-09-15 2014-08-07 Novartis Ag Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer

Also Published As

Publication number Publication date
ES2774101T3 (es) 2020-07-16
EP3093014A1 (en) 2016-11-16
CA2985408A1 (en) 2016-11-17
IL255541A (en) 2018-01-31
EP3294285A1 (en) 2018-03-21
US20160331717A1 (en) 2016-11-17
WO2016180943A1 (en) 2016-11-17
EP3643307A1 (en) 2020-04-29
AU2016259775A1 (en) 2018-01-04
TW201705950A (zh) 2017-02-16
CN108135878A (zh) 2018-06-08
PT3294285T (pt) 2020-03-06
PL3294285T3 (pl) 2020-05-18
JP2018516890A (ja) 2018-06-28
EA201792502A1 (ru) 2018-02-28
EP3294285B1 (en) 2019-12-18
KR20180006417A (ko) 2018-01-17

Similar Documents

Publication Publication Date Title
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
IN2015DN01156A (es)
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MY199705A (en) Heterocyclic compounds as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
TW201613901A (en) New compounds
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
EP3212658A4 (en) 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
MX2017000312A (es) Derivados de isoindolina para usarse en el tratamiento de una infeccion viral.
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
MX379271B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
PH12017501879A1 (en) Methods for treating cancer
MY202127A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder